Why the study?
Do Atractylenolide compounds inhibit platelet activation and thrombosis in preclinical models?
Population
In vitro human platelets and in vivo mouse model of ferric chloride-induced carotid arterial thrombosis
Comparison
Atractylenolide compounds (ATL-1, ATL-2, ATL-3) vs Acetylsalicylic acid and untreated controls
Design
Preclinical
Authors
Loading...
Hypothesis-generating for ATL compounds in thrombosis; leaves open any role in human CAD management.
Do Atractylenolide compounds inhibit platelet activation and thrombosis in preclinical models?
ATL-2 and ATL-3 demonstrate significant antiplatelet and antithrombotic effects in preclinical models, suggesting their potential as novel therapeutic agents for thrombosis prevention.
Chen et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: